An in-depth interview with Dr. Tess Lawrie of EBMC Squared describing the effectiveness of long-time safe medicine ivermectin to treat and prevent covid and how health authorities are systematically ignoring the evidence.
Two doses (300 μg/kg/dose in a gap of 72 hours) of ivermectin chemoprophylaxis reduced COVID-19 infection by 83% among HCWs for one month. Ivermectin is a safe and effective strategy to prevent COVID-19, in the containment of pandemic alongside vaccine. Further research is required to guide the frequency of chemoprevention, acceptability, and cost-effectiveness in the community setting.
Over the past four months, E-BMC Ltd has been working together with the FLCCC to encourage governments around the world to adopt re-purposed existing drugs for the early treatment of
covid-19. One such drug is Ivermectin, a safe medicine which has been used for nearly 40 years to treat parasitic infections. properties as well. E-BMC Ltd’s comprehensive meta-analysis, which has now been published in the peer-reviewed American Journal of Therapeutics, shows that “moderate-certainty evidence” points to a substantial reduction in Covid-19 related deaths with the use of ivermectin.
Dr. Tess Lawrie presents the latest systematic review evidence from RCTs and a selection of resource, equity, acceptability and feasibility considerations related to ivermectin use for COVID-19
Medical experts from around the world joined together to present the very latest real world research on repurposing this safe drug that has the ability to transform global efforts to fight the pandemic. In this talk, speaker Dr. Mobeen Syed provides an overview of ivermectin and how it works against covid-19.
